Buscomine

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Buscomine

Quick Facts

Property Description
Active ingredient Hyoscine Butylbromide (Scopolamine Butylbromide)
Form Tablets, Injectable Solution
Pharmacological class Anticholinergic Agent, Antispasmodic
Common purpose Relief of painful smooth muscle spasm
Origin Semisynthetic Derivative

What is Buscomine and What Type of Drug is it?

Buscomine is a recognized trade name for a medicinal preparation whose sole active ingredient is Hyoscine Butylbromide (INN), a substance broadly classified as an anticholinergic agent and primarily designated as an antispasmodic. This compound is a semisynthetic derivative originating from the natural belladonna alkaloid, scopolamine, specifically tailored to maximize its peripheral action. The unique quaternary ammonium compound structure of Hyoscine Butylbromide prevents its significant passage across the blood-brain barrier. This specialized design feature is recognized for targeting visceral spasm without the typical systemic effects associated with less selective anticholinergics.

Available Forms and General Therapeutic Purpose

Hyoscine Butylbromide is supplied in primary dosage forms including oral tablets and the sterile injectable solution for acute needs via parenteral administration. The core therapeutic purpose of this medicine is to address the underlying cause of spasmodic pain by facilitating smooth muscle relaxation. It achieves this by acting as a muscarinic receptor antagonist, competitively blocking the signals (acetylcholine) that trigger excessive, painful contractions in the gut. This mechanism supports its typical use for rapidly relieving acute episodes of abdominal cramping or other painful spasm within the gastrointestinal and genitourinary tracts. The medicine is broadly classified as a fast-acting agent designed for symptomatic relief of involuntary muscle tension.

What side effects are possible with Buscomine?

The official safety profile of Buscomine (Hyoscine Butylbromide) is primarily defined by its anticholinergic properties, with adverse reactions categorized by frequency and body system in regulatory documentation.

Documented Adverse Reactions

Adverse reactions are classified according to standard regulatory frequency tiers. The most common or expected effects align with the drug's anticholinergic activity and include tachycardia (fast heart rate, especially injectable form), dry mouth, and accommodation disorders or visual disturbances.

Classification Examples of Effects Systems Affected
Common Tachycardia, Dry mouth, Accommodation disorders Cardiac, Gastrointestinal, Eye
Rare Urinary retention (oral form) Renal and Urinary
Not Known Anaphylactic shock, Hypotension, Mydriasis, Confusion (high-dose parenteral) Immune System, Vascular, Eye, Nervous System

Serious Safety Considerations

Serious adverse reactions documented in regulatory sources include anaphylactic shock (which may be fatal, particularly following injection) and severe hypotension (decreased blood pressure). These events are more serious in patients with underlying cardiac conditions such as heart failure or coronary heart disease. The drug's safety information advises that patients receiving the injection should be kept under observation.

Safety-Related Restrictions

Use of Hyoscine Butylbromide is subject to explicit restrictions (contraindications). The medicine must not be used in individuals with conditions that could be aggravated by anticholinergic action, including untreated narrow-angle glaucoma, myasthenia gravis, megacolon, paralytic or obstructive ileus, mechanical stenosis of the gastrointestinal tract, and prostatic hypertrophy with urinary retention. Use during pregnancy and lactation is generally not recommended due to limited data, and the oral tablet is not recommended for children under six years of age.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Hyoscine Butylbromide is documented in regulatory labeling as an exaggeration of known anticholinergic effects. The official manifestations of overdose primarily reflect peripheral muscarinic receptor blockade. Clinical signs of toxicity listed in product information include tachycardia (abnormally fast heart rate), dry mouth, blurred vision due to visual accommodation disturbances, skin flushing, and urinary retention.

Severe Outcomes and Required Actions

In cases of massive overdosage, regulatory documents report potential for severe anticholinergic effects that may involve the central nervous system. These severe outcomes can include coma and respiratory paralysis, which are classified as life-threatening situations. Due to the potential for these serious complications, official guidance mandates that individuals seek immediate medical attention or contact emergency services without delay upon any suspicion of overdose or presentation of severe symptoms.

Overdose Management

Regulatory documentation states that the treatment for Hyoscine Butylbromide overdose is symptomatic and supportive. There is an official statement that no specific antidote is known. However, supportive measures may include gastric lavage or administration of activated charcoal if ingestion was recent. Continuous cardiovascular monitoring and hospital observation are required to manage severe effects and maintain vital functions.

Therapeutic Uses of Buscomine

What Buscomine Treats: Main Uses and Benefits

Buscomine (hyoscine butylbromide) is commonly used to help manage acute symptoms and distress related to smooth muscle spasm in the gastrointestinal tract. This medicine is used for easing symptoms and contributes to improved comfort during periods of heightened symptoms.


Therapeutic Applications

This medicine is applied across domains where additional symptomatic support is needed, particularly for conditions characterized by episodic or fluctuating symptom patterns. Common clinical scenarios include addressing spasms in the gastrointestinal tract, the genito-urinary tract, and providing symptomatic relief for Irritable Bowel Syndrome. It offers symptomatic relief that may help patients cope more steadily with symptom fluctuations.

“It is used in areas where short-term symptom management is appropriate and symptoms create noticeable physiological strain.”

Buscomine is used in clinical settings that involve acute or unstable symptom patterns, assisting with symptomatic management when symptoms become more noticeable.


Quick Fact: Applicable for Acute Symptom Manifestations Buscomine is commonly used across conditions presenting with acute episodes where symptoms may intensify temporarily, requiring short-term supportive assistance.

Eligibility and Restrictions for Use

Who Can and Cannot Use Buscomine?

The official eligibility profile for Buscomine (hyoscine butylbromide) is strictly defined by regulatory documents, identifying specific populations for whom use is prohibited or restricted.

Populations Who Must Not Use the Medicine

Absolute non-eligibility (contraindications) includes patients diagnosed with narrow-angle glaucoma, myasthenia gravis, and specific obstructive conditions. This covers megacolon, paralytic ileus, and physical obstructions like mechanical stenosis in the gut, or prostatic hypertrophy leading to urinary retention. Additionally, patients with a known hypersensitivity to the drug or its excipients must not use it.

Age, Pregnancy, and Conditional Use

Use is generally permitted for adults and adolescents over 12 years.

  • Pediatric Restriction: Oral tablets are not recommended for children under 6 years of age.
  • Reproductive Status: The medicine is officially not recommended for use during pregnancy or while breastfeeding due to insufficient safety data.
  • Formulation-Specific Limits: The injectable solution is contraindicated in patients with cardiac failure or tachycardia. Caution is also required for elderly patients and those with impaired liver or kidney function.

What should I know about interactions with other medicines?

Interactions with other medicines and products — official regulatory information for Buscomine (Hyoscine Butylbromide)

Interaction Scope

Category Details
Medicinal product categories with documented interactions Anticholinergic agents, Dopamine antagonists, Beta-adrenergic agents, Anticoagulant drugs (for route restriction), Antacids.
Mechanistic basis of interactions Pharmacodynamic (intensification of effects, opposing GI motility effects, enhanced heart rate); Delayed absorption of other oral medications.

Interaction Classifications (High-Level)

Classification Details
Interaction severity classification Contraindicated Combination (Injection + Anticoagulant via IM route); Clinically significant Intensification of Effects (with other anticholinergic agents).

Official Interaction Statements

Co-administration with other medicines that share anticholinergic properties, such as tricyclic antidepressants, certain antihistamines, and quinidine, may result in an intensification of anticholinergic effects.

The effect on gastrointestinal motility is diminished when the medicine is used concomitantly with dopamine antagonists, including metoclopramide or domperidone. The tachycardic effects (increased heart rate) may be enhanced when co-administered with beta-adrenergic agents.

For the injectable formulation, intramuscular injection is contraindicated in patients receiving anticoagulant drugs due to the risk of intramuscular haematoma; in such cases, the subcutaneous or intravenous routes must be used. The medicine's ability to reduce gastrointestinal motility may cause the delayed systemic absorption of other orally administered medications. Alcohol may increase the chance of side effects such as drowsiness.

Connection to the overall interaction profile

Regulatory documents establish that the interaction profile is predominantly defined by pharmacodynamic effects that either reinforce or oppose its action. The profile also includes a formal route-based restriction on co-administration of the injectable form with anticoagulants.

Mechanism of Action

Peripheral Muscarinic Receptor Blockade

The drug's primary action is the competitive antagonism of muscarinic acetylcholine receptors (M1, M2, M3) located peripherally in the walls of visceral organs, such as the gut and urinary tract. This blockade prevents the binding of the neurotransmitter acetylcholine (ACh), thereby modulating cholinergic signals originating from the peripheral parasympathetic nervous system. Its unique chemical structure, a quaternary ammonium compound, concentrates this activity away from the central nervous system.


️ Inhibition of the Smooth Muscle Contraction Cascade

By blocking the muscarinic receptors, the drug disrupts the internal cellular cascade, specifically preventing the critical mobilization of ionized calcium (Ca^2+) into the muscle cell. Since calcium is essential for activating the contractile enzyme Myosin Light Chain Kinase (MLCK), this inhibition leads directly to the loss of excessive muscle tension. The resulting physiological effect is spasmolysis, defined as the loss of excessive muscle tension caused by altered cholinergic signaling.


Mechanistic Selectivity and Limitations

The mechanism is specific to visceral smooth muscle and does not affect the skeletal muscle responsible for voluntary movement. The antispasmodic mechanism is specific to smooth muscle tension but does not modulate physiological processes originating from non-spasmodic causes such as inflammation or ischemia.

Dosage and Administration Information

Official Administration Guidelines for Hyoscine Butylbromide

Instructions for the use of this medicine are established for both oral tablets and solution for injection. Adherence to these guidelines is required for correct administration.


Administration Component Instruction
Route of Administration Oral (tablets) or Parenteral Injection (Intravenous, Intramuscular, or Subcutaneous).
Preparation Requirements Tablets must be swallowed whole with water; they should not be broken, crushed, or chewed.
Injection Procedure The injectable solution must be administered via slow intravenous (IV) injection or by intramuscular (IM) injection. The IM route is contraindicated for patients receiving anticoagulant drugs; the IV or SC (subcutaneous) routes must be used instead in these cases.

Dosing and Frequency

Population Standard Dosing Regimen
Adults (Oral) Two 10 mg tablets (20 mg) four times daily. A lower starting dose may be prescribed.
Children 6–11 years (Oral) One 10 mg tablet three times daily.
Adults (Parenteral) 20 mg to 40 mg (1 to 2 ampoules) several times daily, not to exceed a maximum daily dose of 100 mg.
Children (Parenteral) In severe cases, 0.3–0.6 mg/kg bodyweight several times a day. The maximum daily dose should not exceed 1.2 mg/kg.

General Use Constraints

  • Duration of Use: The medicine should not be taken on a continuous daily basis or for extended periods without a medical investigation into the cause of the symptoms.
  • Missed Dose: If a dose is missed, it should be taken as soon as remembered, unless it is nearly time for the next scheduled dose, in which case the missed dose must be skipped. A double dose must never be taken to compensate for a missed dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Buscomine

Evidence for Acute Abdominal Cramping and Spasm

Research has extensively explored how Hyoscine Butylbromide was studied for outcomes related to physical discomfort associated with acute abdominal cramping. The evidence base includes Randomized Controlled Trials (RCTs). These studies were studied for rapid symptom change in populations, including adults and children, who were experiencing sudden episodes of crampy abdominal pain. Researchers primarily examined outcomes describing episodic or acute changes, such as the time required to achieve a measured change in pain scores and the frequency of needing rescue analgesia.

Findings describe patterns observed in the studies that were designed to address episodes where symptoms become more noticeable. However, research reported that in specific acute settings, such as pain related to acute gastroenteritis, some studies data show patterns related to non-significant differences when comparing the study groups. Comparative studies have also examined this medicine against other non-antispasmodic agents, such as acetaminophen, where data show patterns related to how symptoms evolved in the observed populations.


Research in Irritable Bowel Syndrome (IBS) and Genitourinary Spasm

The role of this medicine was evaluated in research exploring symptom patterns in Irritable Bowel Syndrome (IBS), a condition characterized by fluctuating or episodic manifestations. The evidence is derived from older clinical trials and systematic reviews that group antispasmodic treatments. Meta-analyses describe patterns observed in the studies where patient-reported outcomes were monitored across study groups.

Studies have also explored this medicine's use in conditions involving periods of heightened symptoms in the genitourinary system, such as acute renal colic. The research for genitourinary uses has primarily been comparative RCTs against other standard treatments, where findings were mixed regarding the outcomes related to physical discomfort.


Evidence Gaps and Areas of Uncertainty

The overall evidence base is characterized by several gaps and uncertainties. Evidence quality varies across studies, particularly for the IBS indication, where certainty remains low due to reliance on older trials with non-standardized diagnostic criteria. Long-term effects are not fully established because follow-up durations were limited in the core clinical evaluation trials. For conditions like acute renal colic, comparative evidence is lacking when research examined this medicine against other standard pain relievers. These uncertainties highlight areas where future research is still required.

Key Studies & References

  1. A Comprehensive Review of the Effects of Hyoscine Butylbromide in Childhood

Frequently Asked Questions (FAQ)

Common questions about Buscomine (FAQ)

Q: Can Buscomine be used for period pain or menstrual cramps?

A: Official product information describes this medicine's use for relieving painful smooth muscle spasms in the abdomen. Since menstrual cramps are a type of abdominal spasm, regulatory sources indicate the drug is often useful for symptoms linked to period pain.


Q: Does Buscomine contain any ingredients that cause problems for people with specific allergies?

A: The tablet formulation contains inactive ingredients (excipients), such as lactose monohydrate. Regulatory guidance states the medicine is listed as contraindicated in patients with rare hereditary problems like galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption.


Q: Why does Buscomine sometimes cause a fast or increased heart rate?

A: The drug is an anticholinergic agent, meaning it works by blocking muscarinic receptors. While this action relieves spasm, the mechanism may also cause tachycardia, or an increased heart rate, which is documented as an uncommon side effect.


Q: Can taking Buscomine affect my ability to drive or operate machinery?

A: Official documents advise that caution should be exercised when driving or operating machinery. This is because the medicine may cause temporary effects like dizziness or accommodation disorder (visual disturbances). Regulatory information advises avoiding driving or operating machinery if these effects occur.


Q: Does taking Buscomine cause sleepiness or drowsiness?

A: Regulatory documentation lists drowsiness as a possible side effect, though it is not one of the most common ones. It is also specifically noted that the chance of experiencing drowsiness is increased when the medicine is taken alongside alcohol.


Q: What are the typical recommended uses for Buscomine tablets vs. the injection?

A: The oral tablets are generally indicated for the relief of symptoms associated with abdominal and gastrointestinal cramping. The injectable solution is typically reserved for acute spasms, such as renal or biliary colic, or for use in certain diagnostic procedures like MRI scanning to reduce muscle movement.


Q: Why is Buscomine not recommended for people with a bowel blockage?

A: The medicine is listed as a contraindication (use is restricted) in cases of bowel obstruction, such as paralytic ileus. This is because its therapeutic action involves inhibiting gastrointestinal motility (the muscle movement in the gut), which could potentially worsen the existing obstruction.


Q: Is Buscomine the same medication as Buscopan?

A: Regulatory and patient information sources confirm that Buscopan is a widely used trade name for a medicine containing the active ingredient Hyoscine Butylbromide. Buscomine is another trade name for a medicine that contains the same active ingredient.


Q: How quickly does Buscomine start working after taking it?

A: Studies and official summaries describe the medicine as working quickly. Symptom relief for painful cramps is typically reported to begin easing within 15 to 30 minutes after administration of the oral tablets in clinical studies.


Q: How long do the effects of Buscomine usually last?

A: The duration of the clinical effects of the drug is generally reported to be about 4 to 6 hours. This period of action is consistent with the drug’s established dosing schedule.


Q: Is dizziness a possible side effect of Buscomine?

A: Yes, dizziness is listed in regulatory documentation as a possible undesirable effect. It is a known side effect that may occur, sometimes particularly after the administration of the injectable form.


Q: Can Buscomine cause constipation or make existing constipation worse?

A: Constipation is listed in regulatory documentation as a possible adverse effect. This is because the drug's anticholinergic action works by inhibiting the normal muscle movements of the digestive tract, which can contribute to constipation.


Q: Does Buscomine interact with common over-the-counter painkillers like paracetamol or ibuprofen?

A: Official regulatory documents have addressed a combination product containing this drug alongside Paracetamol, indicating that co-administration has been studied and is documented. However, combining it with other drugs may potentially enhance certain anticholinergic side effects.


Q: Can Buscomine be taken with other medicines used for IBS?

A: The drug's interaction profile notes effects when taken with certain other medicines, including those used for IBS. Co-administration with dopamine antagonists may diminish its effect on the gut, while co-administration with other anticholinergic agents may intensify side effects.


Q: Is Buscomine available without a prescription in some places?

A: In many countries, the tablet formulation is available over-the-counter (OTC) or as a General Sales List medicine, particularly for the relief of symptoms of Irritable Bowel Syndrome (IBS). The injectable form typically remains prescription-only.


Q: Does Buscomine have a risk of addiction or abuse?

A: The drug is a quaternary ammonium compound that is documented to poorly cross the blood-brain barrier. This specialized chemical structure is the basis for the regulatory statement that significant Central Nervous System (CNS) effects related to abuse potential are generally not associated with the oral form.


Q: Does Buscomine affect the quality of medical imaging like MRI or colonoscopy?

A: The injectable solution is specifically used during certain diagnostic procedures, such as MRI scans and endoscopy. It works as an antispasmodic, which is intended to reduce movement in the gut and facilitate the diagnostic process.


Q: Does Buscomine cause any changes in sweating or body temperature?

A: Regulatory documents list abnormal sweating or reduced sweating (dyshidrosis/anhidrosis) as an uncommon side effect. This is related to the drug's anticholinergic mechanism.


Q: Are there different versions of Buscomine marketed for different conditions, like IBS vs. general cramps?

A: The same active ingredient is marketed in different product names, such as Buscopan Cramps and Buscopan IBS Relief. These names distinguish products for different patient populations and may be subject to different regulatory conditions, such as maximum pack size limits.


Q: Can Buscomine be taken on an empty stomach?

A: Official product labeling indicates that the oral tablets do not typically cause stomach upset. Therefore, the medicine is generally permitted with or without food, as noted in the official product labeling.

How should Buscomine be stored and disposed of?

How to Store and Dispose of Buscomine

Official regulatory labeling dictates specific conditions for storing and disposing of Buscomine (hyoscine butylbromide) to maintain its stability and ensure safety.

Storage Conditions

Storage requirements vary by formulation and region. Tablets must generally be stored at or below 30 C or 25 C, while the injectable solution is stored at controlled room temperature (15-30 C). The tablets must be kept in the original package and in a dry place to protect them from light. All forms of the medicine must be kept out of the sight and reach of children.

Disposal Instructions

Do not use the medicine after the labeled expiry date. Official guidance mandates that unused or expired Buscomine must not be disposed of via wastewater or household waste. Individuals must ask a pharmacist for instructions on how to properly throw away medicines according to local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Buscomine found in:

A-Z Index: